Many emerging biopharmaceutical companies hire contract research organizations (CROs) because of limited staffing and regulatory experience to help them navigate the regulatory pathway. CROs are instrumental in helping these biopharma overcome obstacles such as clinical trial timeline delays, out-of-scope change orders and cost overruns, especially for smaller biotech companies who cannot afford drastic missteps.

All of the above highlight the need to find a CRO that will be the right fit and consistently responsive to clients’ needs.

To propel the biotech companies we partner with, TD2 utilizes a “value-add” approach, where we strive to supplement their capabilities while filling in the gaps in the internal infrastructure to help develop their plan and process every step of the way.

Hear from TD2 president and CEO, Stephen Gately, and chief operating officer, Tara Frank, about how TD2 uses their suite of capabilities to maximize the CRO and emerging biopharma relationship in this recent Applied Clinical Trials article.

Probiotics in focus: How does L. reuteri affect gut health?

The composition of our intestinal microbiota, may be a measure of our overall health. The presence of an imbalance in the microbial gut community is...

Read more +

CAR T-cell Program Development: Key Considerations

For decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, these treatments are not always...

Read more +

Efficient Data Management: One Way to Expedite the Clinical Development Proces

Debates on the safety and effectiveness of vaccines have captured the public’s attention recently. A vaccine is a preventative strategy for certain...

Read more +


Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.

Skip to content